Synergistic effects of bisphenol A and its substitutes with latent insulin resistance on childhood blood pressure and the potential role of lipid metabolism
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Exposure to bisphenol AF and AP in children is linked to higher blood pressure. Latent insulin resistance (LIR) amplifies these effects, partly via lipid metabolism changes, impacting cardiovascular health.
Area Of Science
- Environmental Health
- Pediatric Cardiology
- Endocrinology
Background
- Childhood hypertension is a significant public health issue with long-term cardiovascular risks.
- The impact of bisphenol A (BPA) substitutes, endocrine-disrupting chemicals, on children's cardiovascular and metabolic health is not well understood.
Purpose Of The Study
- To investigate the association between childhood exposure to BPA substitutes and blood pressure.
- To examine the modifying role of latent insulin resistance (LIR) and lipid metabolic pathways in this association.
Main Methods
- Analysis of repeated bisphenol measurements and blood pressure in 747 children from a prospective cohort.
- Utilized mixed-effects models and generalized estimating equations for statistical assessment.
- Lipidomic profiling on a subsample, with grouping by bisphenol exposure and triglyceride-glucose (TyG) index, followed by enrichment and mediation analyses.
Main Results
- Exposure to bisphenol AF (BPAF) and bisphenol AP (BPAP) was positively associated with higher systolic blood pressure z-scores and increased risk of elevated blood pressure.
- Children with concurrent high BPAF/BPAP exposure and high TyG index showed lipid dysregulation linked to elevated childhood blood pressure.
- Dysregulated lipids, mainly lysoglycerophospholipids, were enriched in lipid-mediated signaling pathways. Specific lipids mediated the interaction between BPAF/BPAP, LIR, and blood pressure.
Conclusions
- Bisphenol AP and AF are significantly associated with elevated blood pressure in children.
- Latent insulin resistance exacerbates the adverse effects of BPAF/BPAP on blood pressure, mediated by lipidomic alterations.
- Glycerophospholipid and glycerolipid metabolism pathways are implicated in the adverse cardiovascular effects of BPA substitutes in children.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...